Labatec Pharma SA: Switzerland and the MENA region including Bahrain, Iraq, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, UAE, Algeria, and Morocco Pharmbio Korea Inc.: South Korea Biosidus: Colombia, ...
Analysts expected Eli Lilly’s Forteo to be the big challenge standing in the way of new Radius bone drug Tymlos. But Express Scripts apparently has other ideas. On Monday, the PBM giant said Forteo ...
Full-Year 2019 TYMLOS U.S. net revenue exceeds financial guidance, surpassing $172M. TYMLOS exits 2019 with 52% market share in new patients1, on track for market leadership in 2020. Radius delivers ...
Radius Health Inc. won FDA approval, albeit mildly delayed, of injected Tymlos (abaloparatide) for postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic ...
WALTHAM, Mass., March 17, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing ...
Tymlos (abaloparatide) is not known to interact with alcohol, other medications, or supplements. However, certain health conditions may increase the risk of harmful effects. An interaction can occur ...
Results showed that treatment with abaloparatide for 12 months resulted in significant increases in bone mineral density compared with placebo. The Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results